Trial
NCT04252586
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jazz Pharmaceuticals
Collaborators
GW Pharmaceuticals Ltd
Condition
Rett Syndrome
Intervention
GWP42003-P
Why stopped
Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-08